Jiachang Hong

Jiachang Hong

Auto-generated profile, based on publicly available information

Jiachang Hong

Tongji University

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2026 in Advanced Science
Verified
Journal Article
Open access
JHJiachang Hong
Jiachang Hong
PJPenghao Ji
Penghao Ji
JAJinxi An
Jinxi An
JHJunchao Huang
Junchao Huang
ZBZiheng Bu
Ziheng Bu
PWPeng Wu
Peng Wu
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial inflammation and progressive joint destruction driven by macrophage polarization and osteoclast activation. Current therapies lack lesion‐specificity and cause systemic side effects, highlighting the need for targeted treatment strategies. Here, we developed carrier‐free myricetin‐arginine conjugate nanozymes (MANZs) via a Mannich reaction‐mediated conjugation of l ‐arginine and myricetin, followed by self‐assembly driven by noncovalent interaction. The MANZs selectively target M1 macrophages via cationic amino acid transporter 2 (CAT2)‐mediated uptake, facilitating preferential accumulation in inflamed joints. MANZs exert multi‐modal therapeutic effects by scavenging reactive oxygen species (ROS), repolarizing M1 macrophages, and inhibiting osteoclast differentiation. In a collagen‐induced arthritis (CIA) mouse model, MANZs significantly alleviated joint swelling, synovitis, and bone erosion without systemic toxicity. This work establishes a promising paradigm for RA therapy by integrating cationic amino acids with natural polyphenols into a self‐assembled, target‐specific nanoplatform with high biocompatibility and translational potential.

26 August 2026 in ACS Nano
Verified
Journal Article
Closed access
PJPenghao Ji
Penghao Ji
CLChengjie Li
Chengjie Li
YTYang Tang
Yang Tang
JHJiachang Hong
Jiachang Hong
WLWei Liu
Wei Liu
JSJianlin Shi
Jianlin Shi